Pharmacotherapy for anxiety and comorbid alcohol use disorders

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Ipser, Jonathan C ^a   Wilson, Don ^a   Akindipe, Taiwo O ^a   Sager, Carli ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DESIPRAMINE; NALTREXONE; PAROXETINE; PLACEBO; SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL ABSTINENCE; ALCOHOLISM; ANORGASMIA; ANXIETY DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DSM-III; DSM-IV; EJACULATION DISORDER; FATIGUE; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; METHODOLOGY; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; XEROSTOMIA; ALCOHOL-RELATED DISORDERS; ANXIETY; ANXIETY DISORDERS; PHOBIA, SOCIAL; PUBLISHING; STRESS DISORDERS, POST-TRAUMATIC;

ALCOHOL-RELATED DISORDERS; ANXIETY; ANXIETY DISORDERS; BUSPIRONE; COMORBIDITY; DESIPRAMINE; HUMANS; PAROXETINE; PHOBIA, SOCIAL; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84925320945     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007505.pub2     Document Type: Review

References (150)

1. Book SW, Thomas SE, Randall PK, Randall C. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. Journal of Anxiety Disorders 2008;22(2):310-8.
2. Thomas SE, Randall PK, Book SW, Randall CL. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research 2008;32(1):77-84.
3. Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. Journal of Nervous and Mental Diseases 2006;194(9):690-6.
4. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcoholism, Clinical and Experimental Research 2005;29(3):395-401.
5. Brady KT, Sonne SC, Killeen T, Simpson K, Randall C, Back SE, et al. Sertraline in comorbid PTSD/alcohol dependence. Proceedings of the 65th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2003 Jun 14-19; Florida 2003.
6. Labbate LA, Sonne SC, Randal CL, Anton RF, Brady KT. Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders?. Comprehensive Psychiatry 2004;45(4):304-10.
7. Sonne SC, Back SE, Diaz Zuniga C, Randall CL, Brady KT. Gender differences in individuals with comorbid alcohol dependence and post-traumatic stress disorder. American Journal on Addictions 2003;12(5):412-23.
8. Petrakis I, Jane JS, O'Brien E, Keegan K, Ralevski E, Desai N. Effect of depression on outcomes in a clinical trail evaluating antidepressants +/- naltrexone for treatment of alcohol dependence and PTSD. Alcoholism, Clinical and Experimental Research 2013;37:19A.
9. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology 2012;37(4):996-1004.
10. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression and Anxiety 2001;14(4):255-62.
11. Tollefson GD, Lancaster SP, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in theremission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacology Bulletin 1991;27(2):163-70.
12. Tollefson GD, Montague-Clouse J, Lancaster SP. Buspirone in comorbid alcohol dependency and generalized anxiety disorders. Drug Therapeutics 1990;20 Suppl:35-51.
13. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). Journal of Clinical Psychopharmacology 1992;12(1):19-26.
14. Batki SL, Lasher BA, Heinz AJ, Herbst E, Metzler T, Prathikanti S, et al. Risk-taking, impulsivity, memory and executive functioning as outcome predictors in a trial of topiramate for alcohol dependence in veterans with PTSD. Alcoholism, Clinical and Experimental Research 2012;36:226A.
15. Batki SL, Lasher BA, Herbst E, Prathikanti S, Metzler T, Tarasovsky G, et al. Topiramate treatment of alcohol dependence in veterans with PTSD: baseline alcohol use and PTSD severity. American Journal on Addictions 2011;21(4):382.
16. Batki SL, Lasher BA, Metzler T, Heinz AJ, Herbst E, Waldrop A, et al. Predictors of outcome in a pilot controlled trial of topiramate for alcohol dependence in veterans with PTSD. Alcoholism, Clinical and Experimental Research 2013:17A.
17. Kalapatapu RK, Delucchi KL, Lasher, BA, Vinogradov S, Batki SL. Alcohol use biomarkers predicting cognitive performance: a secondary analysis in veterans with alcohol dependence and posttraumatic stress disorder. Military Medicine 2013;178(9):974-80.
18. Santos G-M, Lasher BA, Heinz AJ, Kalapatapu R, Herbst E, Metzler T, et al. Urinary ethyl glucuronide and ethyl sulfate testing to evaluate the efficacy of topiramate treatment of alcohol dependence in veterans with PTSD. Alcoholism, Clinical and Experimental Research 2013;37:19A.
19. Caponi A, Realini R, Macciocchi A. A double-blind clinical trial of camazepam vs bromazepam in the treatment of anxio-depressive syndrome in alcoholic patients [Studio doppio cieco camazepam versus bromazepam nel trattamento delle sindromi ansioso-depressive in soggetti etillisti]. Progresso Medico 1985;41(12):731-7.
20. Ciraulo DA, Barlow DH, Gulliver SB, Farchione T, Morissette SB, Kamholz BW, et al. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behaviour Research and Therapy 2013;51(11):729-35.
21. Guardia J. Clinical trial with ziprasidone for the treatment of psychiatric pathology, not being a severe mental disorder, associated to alcohol dependence. clinicaltrials.gov/ct2/show/NCT00197951 (accessed February 2014).
22. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Archives of General Psychiatry 1994;51(9):720-31.
23. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJ, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence 1993;33(2):157-63.
24. Krupitsky E, Yerish S, Rybakova K, Kiselev A. Single blind placebo controlled randomized clinical trial of trazodon for alcoholism comorbid with affective disorders. Alcoholism, Clinical and Experimental Research 2013;37:18A.
25. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. Journal of Affective Disorders 2003;76(1-3):279-84.
26. Loo H, Guelfi JD, Malka R, Brion S, Cottin M, Gailledreau J, et al. Anxiolytic efficacy and tolerance of tetrabamate in anxious patients abusing alcohol. Multicenter double-blind versus placebo study [Efficacité anxiolytique et tolérance du tétrabamate chez des patients anxieux abusant de l'alcool. Etude multicentrique en double insu contre placebo]. Encephale 1986;12(5):291-7.
27. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism, Clinical and Experimental Research 1992;16(6):1007-13.
28. Moak DH, Anton RF, Malcolm R, Randall CL, Brady K. Alcoholic subjects with anxiety disorder: characteristics of completers and noncompleters in a pharmacologic study. American Journal on Addictions 1993;2(1):39-47.
29. Oluwadara BO, Roache JD, Guajardo J, Raj JJ. Correlation pattern of alcohol use and PTSD symptoms among combat veterans in treatment for comorbid PTSD and alcohol use disorder. Alcoholism, Clinical and Experimental Research 2013;37:331A.
30. Roache JD, Guajardo J, Raj JJ. Preliminary examination of alcoholism subtypes in PTSD and alcohol use dual diagnosis. Alcoholism, Clinical and Experimental Research 2013;37(Suppl 2):331A.
31. Schadé A, Marquenie LA, van Balkom AJ, Koeter MM, van den Brink W, van Dyck R. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomised controlled trial [Effectiviteit van een toegevoegde behandeling voor angstklachten bij alcoholafhankelijke patienten met een fobische stoornis]. Tijdschrift Voor Psychiatrie 2008;50(3):137-48.
32. Schadé A, Marquenie LA, van Balkom AJ, Koeter MW, de Beurs E, van den Brink W, et al. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcoholism, Clinical and Experimental Research 2005;29(5):794-800.
33. Farchione TJ. CBT and venlafaxine treatments for anxiety in alcoholism. clinicaltrials.gov/ct2/show/NCT00248612 (accessed August 2013).
34. Sonne SC, Brady KT. Paroxetine treatment in outpatients with comorbid PTSD and substance dependence. clinicaltrials.gov/ct2/show/NCT00330239 (accessed February 2014).
35. Sattar P. 12 week prospective double blind placebo controlled randomized trial of Seroquel SR for alcohol dependence and comorbid anxiety. clinicaltrials.gov/ct2/show/NCT00352469 (accessed August 2013).
36. Fischer B. A 14-week randomized, placebo-controlled study of topiramate for alcohol use disorders in veterans with posttraumatic stress disorder. clinicaltrials.gov/ct2/show/NCT01408641 (accessed February 2014).
37. Simpson T. A placebo-controlled trial of prazosin in individuals with co-occurring alcohol dependence and PTSD. clinicaltrials.gov/ct2/show/NCT01518972 (accessed February 2014).
38. Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, et al. A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcoholism, Clinical and Experimental Research 1995;19(2):462-8.
39. Sinha R. Prazosin to reduce stress-induced alcohol/drug craving and relapse. clinicaltrials.gov/ct2/show/NCT00585780 (accessed August 2013).
40. Ralevski E. The use of prazosin for treatment of patients with alcohol dependence (AD) and post traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/NCT00744055 (accessed August 2013).
41. Batki, SL. A controlled trial of topiramate treatment for alcohol dependence in veterans with PTSD. clinicaltrials.gov/ct2/show/NCT01749215 (accessed February 2014).
42. Petrakis I. Zonisamide in addition to enhanced cognitive processing therapy-C (E-CPT-C) for veterans with PTSD and comorbid alcohol dependence. clinicaltrials.gov/show/NCT01847469 (accessed February 2014).
43. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica Supplementum 2004;420:28-37.
44. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-8.
45. Alvanzo AAH, Storr CL, Mojtabai R, Green KM, Pacek RL, La Flair LN, et al. Gender and race/ethnicity differences for initiation of alcohol-related service use among persons with alcohol dependence. Drug and Alcohol Dependence 2014;140:48-55.
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
47. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
48. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
49. Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. Journal of Nervous and Mental Disease 2006;194(9):690-6.
50. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 2003;183:498-506.
51. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology 2014;28:403-39.
52. Baxter AJ, Vos T, Scott KM, Ferrari AJ, Whiteford HA. The global burden of anxiety disorders in 2010. Psychological Medicine 2014;22:1-12.
53. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
54. Berenz EC, Coffey SF. Treatment of co-occurring posttraumatic stress disorder and substance use disorders. Current Psychiatry Reports 2012;14(5):469-77.
55. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. American Journal of Psychiatry 1993;150(9):1430.
56. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behavior Therapy 1990;21:187-8.
57. Booth BM, Kirchner J, Fortney J, Ross R, Rost K. Rural at-risk drinkers: correlates and one-year use of alcoholism treatment services. Journal of Studies on Alcohol 2000;61:267-77.
58. Boschloo L, Vogelzangs N, van den Brink W, Smit JH, Veltman DJ, Beekman ATF, et al. Depressive and anxiety disorders predicting first incidence of alcohol use disorders: results of the Netherlands Study of Depression and Anxiety (NESDA). Journal of Clinical Psychiatry 2013;74:1233-40.
59. Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addictive Behaviors 2000;25(4):593-7.
60. Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatric Quarterly 1993;64(2):135-49.
61. Brookwell L, Hogan C, Healy D, Mangin D. Ninety-three cases of alcohol dependence following SSRI treatment. International Journal of Risk & Safety in Medicine 2014;26:99-107.
62. Bühler M, Mann K. Alcohol and the human brain: a systematic review of different neuroimaging methods. Alcoholism, Clinical and Experimental Research 2011;35:1771-93.
63. Cohen E, Feinn R, Arias A, Kranzler HR. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence 2007;86:214-21.
64. Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. British Journal of Psychiatry 2000;176:379-86.
65. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 2006;51(8 Suppl 2):9S-91S.
66. Dawson DA, Goldstein RB, Grant BF. Factors associated with first utilization of different types of care for alcohol problems. Journal of Studies on Alcohol and Drugs 2012;73:647-56.
67. Dawson DA, Goldstein RB, Grant BF. Differences in the profiles of DSM-IV and DSM-5 alcohol use disorders: implications for clinicians. Alcoholism, Clinical and Experimental Research 2013;37 Suppl 1:E305-13.
68. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575-600.
69. Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
70. Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results: follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374-8.
71. Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol and Alcoholism 2001;36(3):249-55.
72. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
73. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multi-center study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 2003;23(3):240-9.
74. Gahr M, Franke B, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. Journal of Addiction Medicine 2013;7:147-9.
75. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
76. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
77. Hamilton M. Standardised assessment and recording of depressive symptoms. Psychiatria, Neurologia, Neurochirurgia 1969;72:201-5.
78. Hasin D. Classification of alcohol use disorders. Alcohol Research & Health 2003;27(1):5-17.
79. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 2007;64(7):830-42.
80. Higgins JTP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-60.
81. Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
82. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
83. Hoertel N, Le Strat Y, Blanco C, Lavaud P, Dubertret C. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depression and Anxiety 2012;29:614-20.
84. Hofmann SG, Wu JQ, Boettcher H, Sturm J. Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis. Quality of Life Research 2013;23(4):1141-53.
85. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.MR000006.pub3]
86. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosomatic Medicine 1979;41(3):209-18.
87. Johnson BA, Ait-Daoud N, Ma JZ, Wang Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcoholism, Clinical and Experimental Research 2003;27(11):1773-9.
88. Keane TM, Caddell JM, Taylor KL. Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. Journal of Consulting and Clinical Psychology 1988;56(1):85-90.
89. Kendall PC, Safford S, Flannery-Schroeder E, Webb A. Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. Journal of Consulting and Clinical Psychology 2004;72(2):276-87.
90. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. American Journal of Orthopsychiatry 1996;66(1):17-31.
91. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997;54(4):313-21.
92. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry 1985;142(11):1259-64.
93. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues in Clinical Neuroscience 2011;13(4):423-37.
94. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism, Clinical and Experimental Research 2006;20(9):1534-41.
95. Kranzler HR, Armeli S, Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcoholism, Clinical and Experimental Research 2012;36(4):739-44.
96. Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Archives of General Psychiatry 2006;63(9):957-68.
97. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. American Journal of Psychiatry 1990;147(6):685-95.
98. Kushner MG, Abrams K, Thuras P, Hanson KL, Brekke M, Sletten S. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcoholism, Clinical and Experimental Research 2005;29(8):1432-43.
99. Kwo PY, Ramchandani VA, O'Connor S, Amann D, Carr LG, Sandrasegaran K, et al. Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass. Gastroenterology 1998;115:1552-7.
100. Lev-Ran S, Balchand K, Lefebvre L, Araki KF, Le Foll B. Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: a review. Canadian Journal of Psychiatry 2012;57(6):342-9.
101. Liappas J, Paparrigopoulos T, Tzavellas E, Rabavilas A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro-psychopharmacology & Biological Psychiatry 2005;29:55-60.
102. Liebowitz MR. Social phobia. Modern Problems in Pharmacopsychiatry 1987;22:141-73.
103. Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Human Psychopharmacology 2002;17(4):181-5.
104. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21(16):2313-24.
105. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. Journal of General Internal Medicine 2002;17(5):349-55.
106. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry 2001;158(12):1982-8.
107. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety 2007;24(2):77-84.
108. McLean CP, Asnaani A, Litz BT, Hofmann SGJ. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. Journal of Psychiatric Research 2011;45:1027-35.
109. McLellan AT, Parikh G, Bragg A, Cacciola J, Fureman B, Incmikoski R. Addiction Severity Index: Administration Manual. 5th Edition. Philadelphia: Pennsylvania Veterans' Administration Center for Studies of Addiction, 1990.
110. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
111. Morris EP, Stewart SH, Ham LS. The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clinical Psychology Review 2005;25(6):734-60.
112. Mukherjee S, Das SK, Vaidyanathan K, Vasudevan, DM. Consequences of alcohol consumption on neurotransmitters - an overview. Current Neurovascular Research 2008;5(4):266-72.
113. National Institute for Health and Care Excellence Clinical Guideline 31. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder, 2005. www.nice.org.uk/guidance/cg031 (accessed 30 December 2014).
114. Oakman J, Van Ameringen M, Mancini C, Farvolden P. A confirmatory factor analysis of a self-report version of the Liebowitz Social Anxiety Scale. Journal of Clinical Psychology 2003;59:149-61.
115. Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(2):141-9.
116. Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behavior. International Journal of Clinical Pharmacology and Therapeutics 2013;51:441-2.
117. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biological Psychiatry 2006;60(7):777-83.
118. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research 2000;24(7):1041-9.
119. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 2005;25(2):151-8.
120. Project MATCH. Project MATCH (Matching Alcoholism Treatment to Client Heterogeneity): rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcoholism, Clinical and Experimental Research 1993;17(6):1130-45.
121. Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcoholism, Clinical and Experimental Research 2001;25(2):210-20.
122. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8.
123. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
124. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 2005;62(9):1022-30.
125. Roberts NP, Roberts PA, Bisson JI. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD010204]
126. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150-3.
127. Schadé A, Marquenie LA, Van Balkom AJ, De Beurs E, Van Dyck R, Van Den Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. Alcohol and Alcoholism 2003;38(3):255-62.
128. Schadé A, Marquenie LA, van Balkom AJ, Koeter MW, de Beurs E, van den Brink W, et al. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcoholism, Clinical and Experimental Research 2005;29(5):794-800.
129. Schuckit MA, Monteiro MG. Alcoholism, anxiety and depression. British Journal of Addiction 1988;83(12):1373-80.
130. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin - results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology 2010;66:947-53.
131. Schweizer E, Rickels K, Lucki I. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. New England Journal of Medicine 1986;314:719-20.
132. Shah R, Uren Z, Baker A, Majeed A. Deaths from antidepressants in England and Wales 1993-1997: analysis of a new national database. Psychological Medicine 2001;31:1203-10.
133. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. Multicenter collaborative Panic Disorder Severity Scale. American Journal of Psychiatry 1997;154:1571-5.
134. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3:89-95.
135. Smith JP, Randall CL. Anxiety and alcohol use disorders: comorbidity and treatment considerations. Alcohol Research 2012;34:414-31.
136. Sobell LC, Sobell MB. Timeline Follow-Back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ editor(s). Measuring Alcohol Consumption: Psychological and Biological Methods. Totowa: Humana Press, 1992:41-72.
137. Sofuoglu M, Rosenheck R, Petrakis I. Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. Addictive Behaviors 2014;39:428-33.
138. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technology Assessment 2000;4(10):1-115.
139. Spitzer R, Williams J, Gibbons M. Instructional Manual for the Structured Clinical Interview for DSM-IV. New York: New York State Psychiatric Institute, 1996.
140. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectrums 2009;14(1 Suppl 1):25-30.
141. Stewart SH, Conrod PJ. Anxiety disorder and substance use disorder co-morbidity: common themes and future directions. Anxiety and Substance Use Disorders: the Vicious Cycle of Comorbidity. Series in Anxiety and Related Disorders. New York: Springer, 2008:239-57.
142. Thomas SE, Randall PK, Book SW, Randall CL. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research 2008;32(1):77-84.
143. Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug and Alcohol Dependence 2005;78(1):1-22.
144. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 2001;62(11):860-8.
145. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2007;68:201-20.
146. Ugochukwu C, Bagot KS, Delaloye S, Pi S, Vien L, Garvey T, et al. The importance of quality of life in patients with alcohol abuse and dependence. Harvard Review of Psychiatry 2013;21:1-17.
147. Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
148. Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS, et al. Gender differences in generalized anxiety disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Journal of Clinical Psychiatry 2008;69:1606-16.
149. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
150. Watkins KE, Hunter SB, Burnam MA, Pincus HA, Nicholson G. Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder. Psychiatric Services 2005;56(8):913-26.